PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study
- PMID: 28361462
- PMCID: PMC5380508
- DOI: 10.1007/s13300-017-0257-4
PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study
Abstract
Introduction: Peroxisome proliferator-activated receptor-α (PPAR-α) agonists can regulate metabolism and protect the cardiovascular system. This study investigated the effects of PPAR-α agonist fenofibrate on insulin resistance in patients with impaired glucose tolerance (IGT).
Methods: This research evaluated cross-sectional and interventional studies. 191 subjects with IGT were divided into a hypertriglyceridemia group (HTG group, n = 118) and a normal triglyceride (TG) group (NTG group, n = 73). 79 subjects with normal glucose tolerance were recruited as a control group. The HTG group was treated with fenofibrate (200 mg/day) for 12 weeks. The homeostatic model assessment index 2 (HOMA2) and the McAuley index (McA) were calculated.
Results: HOMA2 for β-cell function (HOMA2-%B) was 93.47 ± 26.28, 68.47 ± 21.29, and 79.92 ± 23.15 in HTG, NTG, and control groups, respectively. HOMA2 for insulin sensitivity (HOMA2-%S) was 48.40 (39.70, 68.70), 110.20 (62.55, 141.95), and 101.20 (79.90, 140.10) in HTG, NTG, and control groups, respectively. HOMA2 for insulin resistance (HOMA2-IR) was 2.09 (1.46, 2.52), 0.92 (0.70, 1.61), and 0.99 (0.71, 1.25) in HTG, NTG, and control groups, respectively. McA was 5.05 ± 0.76, 7.99 ± 1.79, and 8.34 ± 1.55 in HTG, NTG, and control groups, respectively. The HTG group had higher HOMA2-%B and HOMA2-IR, and lower HOMA2-%S and McA than NTG and control groups (P < 0.001 for all). Fenofibrate decreased HOMA2-%B and HOMA2-IR and increased HOMA2-%S and McA in the HTG group (HOMA2-%B: from 93.47 ± 26.28 to 89.34 ± 23.53, P = 0.018; HOMA2-%S: from 48.40 (39.70, 68.70) to 56.75 (44.88, 72.53), P < 0.001; HOMA2-IR: from 2.07 (1.46, 2.52) to 1.76 (1.38, 2.30), P < 0.001; McA: from 5.05 ± 0.76 to 9.34 ± 0.88, P < 0.001).
Conclusion: PPAR-α agonists improve parameters of glucoregulation in IGT patients with hypertriglyceridemia.
Keywords: Hypertriglyceridemia; Impaired glucose tolerance; Insulin resistance; Peroxisome proliferator-activated receptor-α; β-Cell function.
Similar articles
-
PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance.PPAR Res. 2016;2016:6232036. doi: 10.1155/2016/6232036. Epub 2016 Feb 29. PPAR Res. 2016. PMID: 27034649 Free PMC article.
-
PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.PPAR Res. 2015;2015:924131. doi: 10.1155/2015/924131. Epub 2015 Nov 26. PPAR Res. 2015. PMID: 26693220 Free PMC article.
-
Studies in hypertriglyceridaemia, III: Glucose tolerance, insulin sensitivity and indices of adipose tissue lipolysis in randomly selected non-diabetic hypertriglyceridaemic Swedish men.Eur J Clin Invest. 1995 Oct;25(10):769-76. doi: 10.1111/j.1365-2362.1995.tb01956.x. Eur J Clin Invest. 1995. PMID: 8557064
-
PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.Med Sci Monit. 2016 Mar 5;22:743-51. doi: 10.12659/msm.897307. Med Sci Monit. 2016. PMID: 26944934 Free PMC article.
-
Triglycerides and gallstone formation.Clin Chim Acta. 2010 Nov 11;411(21-22):1625-31. doi: 10.1016/j.cca.2010.08.003. Epub 2010 Aug 10. Clin Chim Acta. 2010. PMID: 20699090 Review.
Cited by
-
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review.Diabetes Metab J. 2024 Mar;48(2):184-195. doi: 10.4093/dmj.2023.0168. Epub 2024 Jan 26. Diabetes Metab J. 2024. PMID: 38273789 Free PMC article. Review.
-
Hepatic Ago2 Regulates PPARα for Oxidative Metabolism Linked to Glycemic Control in Obesity and Post Bariatric Surgery.Endocrinology. 2021 Apr 1;162(4):bqab007. doi: 10.1210/endocr/bqab007. Endocrinology. 2021. PMID: 33567453 Free PMC article.
-
Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.Drug Des Devel Ther. 2024 Nov 16;18:5239-5253. doi: 10.2147/DDDT.S490772. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39575188 Free PMC article. Clinical Trial.
-
Orphan receptor GPR50 attenuates inflammation and insulin signaling in 3T3-L1 preadipocytes.FEBS Open Bio. 2023 Jan;13(1):89-101. doi: 10.1002/2211-5463.13516. Epub 2022 Dec 13. FEBS Open Bio. 2023. PMID: 36333974 Free PMC article.
References
-
- Rachid TL, Penna-de-Carvalho A, Bringhenti I, Aguila MB, Mandarim-de-Lacerda CA, Souza-Mello V. Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice. Mol Cell Endocrinol. 2015;402:86–94. doi: 10.1016/j.mce.2014.12.027. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous